Nu.Q Vet Cancer Test Expansion
The Nu.Q Vet Cancer Test expanded access to over 20 countries and sold approximately 120,000 tests in 2024, doubling the previous year and resulting in a 75% increase in vet revenue compared to 2023.
Significant Revenue Growth
VolitionRx recorded $1.2 million in revenue for 2024, a 59% increase from 2023. Nu.Q Vet Cancer Test revenue grew by 75%, and Nu.Q Discover revenue grew by 40%.
Cost Reduction Success
Operating expenses were reduced by 23% year-over-year, with a 31% reduction in the second half of 2024 compared to the previous year.
Nu.Q Cancer Clinical Progress
The Nu.Q Cancer platform demonstrated its ability to differentiate between malignant and benign pulmonary nodules in an 800-patient study, with further validation studies underway.
Nu.Q NETs Sepsis Marker Success
Nu.Q NETs test showed promising results across multiple studies as a surrogate marker for neutrophil extracellular traps (NETs) in sepsis, generating interest from key opinion leaders and licensing partners.
Nu.Q Discover Pharmaceutical Partnerships
VolitionRx entered into its first human clinical study partnership with a leading pharmaceutical company, expected to generate significant revenue and validate the Nu.Q Discover program.